Losmapimod

• Description:

  Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].

• Product Name Alternative:

  GSK-AHAB; GW856553X; SB856553

• UNSPSC:

  12352005

• Hazard Statement:

  H361

• Target:

  Autophagy; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy; MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Losmapimod.html

• Concentration:

  10mM

• Purity:

  99.94

• Solubility:

  DMSO : 27.5 mg/mL (ultrasonic) |Ethanol : 33.33 mg/mL (ultrasonic)

• Smiles:

  CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F

• Molecular Formula:

  C22H26FN3O2

• Molecular Weight:

  383.46

• Precautions:

  H361

• References & Citations:

  [1]Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330 (3) :964-70.|[2]Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  [585543-15-3]